PDF(Pubmed)
Abstract：
UNASSIGNED: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent approved for the treatment of moderate to severely active inflammatory bowel disease (IBD: ulcerative colitis [UC] and Crohn\'s disease [CD]).
UNASSIGNED: A systematic literature review (SLR) of real-world studies was conducted to assess the effectiveness of dose escalation of vedolizumab every 8 weeks (Q8W) during maintenance treatment to achieve a response in patients who were either vedolizumab responders experiencing secondary loss of response (SLOR) or non-responders. MEDLINE and EMBASE databases were searched from January 2014 to August 2021.
UNASSIGNED: Screening of SLR outputs identified 72 relevant real-world study publications featuring dose escalation of vedolizumab maintenance therapy. After qualitative review, ten eligible studies (9 articles, 1 abstract) were identified as reporting clinical response and/or clinical remission rates following escalation of intravenous vedolizumab 300 mg Q8W maintenance dosing to every 4 weeks (Q4W) maintenance dosing in adult patients with UC/CD (≥10 patients per study). Overall, 196/395 (49.6%) patients with IBD had a response within 54 weeks of vedolizumab maintenance dose escalation. Although definitions for clinical response/remission varied across the 10 studies, clinical response rates after escalated vedolizumab Q8W maintenance dosing ranged from 40.0% to 73.3% (9 studies) and from 30.0% to 55.8% for remission (4 studies) over a range of 8 to <58 weeks\' follow-up.
UNASSIGNED: This synthesis of real-world effectiveness data in vedolizumab-treated patients with IBD indicates that approximately half were able to achieve or recapture clinical response after escalating vedolizumab maintenance dosing.
UNASSIGNED: A systematic literature review (SLR) of real-world studies was conducted to assess the effectiveness of dose escalation of vedolizumab every 8 weeks (Q8W) during maintenance treatment to achieve a response in patients who were either vedolizumab responders experiencing secondary loss of response (SLOR) or non-responders. MEDLINE and EMBASE databases were searched from January 2014 to August 2021.
UNASSIGNED: Screening of SLR outputs identified 72 relevant real-world study publications featuring dose escalation of vedolizumab maintenance therapy. After qualitative review, ten eligible studies (9 articles, 1 abstract) were identified as reporting clinical response and/or clinical remission rates following escalation of intravenous vedolizumab 300 mg Q8W maintenance dosing to every 4 weeks (Q4W) maintenance dosing in adult patients with UC/CD (≥10 patients per study). Overall, 196/395 (49.6%) patients with IBD had a response within 54 weeks of vedolizumab maintenance dose escalation. Although definitions for clinical response/remission varied across the 10 studies, clinical response rates after escalated vedolizumab Q8W maintenance dosing ranged from 40.0% to 73.3% (9 studies) and from 30.0% to 55.8% for remission (4 studies) over a range of 8 to <58 weeks\' follow-up.
UNASSIGNED: This synthesis of real-world effectiveness data in vedolizumab-treated patients with IBD indicates that approximately half were able to achieve or recapture clinical response after escalating vedolizumab maintenance dosing.
摘要：
未经批准：Vedolizumab是一种肠道选择性抗淋巴细胞运输药物，被批准用于治疗中度至重度活动性炎症性肠病（IBD：溃疡性结肠炎[UC]和克罗恩病[CD]）。
UNASSIGNED：进行了真实世界研究的系统文献综述（SLR），以评估维多珠单抗在维持治疗期间每8周（Q8W）剂量递增的有效性，以在维多珠单抗反应者经历继发性反应丧失（SLOR）或无反应者中实现反应。从2014年1月至2021年8月搜索了MEDLINE和EMBASE数据库。
UNASSIGNED：SLR输出的筛选确定了72篇相关的真实世界研究出版物，其特征是维多珠单抗维持治疗的剂量递增。经过定性审查,十项符合条件的研究(9篇文章，1摘要）被确定为在UC/CD成年患者（每个研究≥10名患者）中将维多珠单抗300mgQ8W维持剂量增加至每4周（Q4W）维持剂量后报告临床反应和/或临床缓解率。总的来说,196/395（49.6%）IBD患者在维多珠单抗维持剂量递增的54周内有反应。尽管临床反应/缓解的定义在10项研究中有所不同，在8~<58周的随访期间,维多珠单抗Q8W维持给药后的临床缓解率为40.0%~73.3%(9项研究),缓解率为30.0%~55.8%(4项研究).
UNASSIGNED：这项对接受维多珠单抗治疗的IBD患者的真实世界有效性数据的合成表明，在逐步增加维多珠单抗维持剂量后，大约一半能够实现或重新获得临床反应。
UNASSIGNED：进行了真实世界研究的系统文献综述（SLR），以评估维多珠单抗在维持治疗期间每8周（Q8W）剂量递增的有效性，以在维多珠单抗反应者经历继发性反应丧失（SLOR）或无反应者中实现反应。
UNASSIGNED：SLR输出的筛选确定了72篇相关的真实世界研究出版物，其特征是维多珠单抗维持治疗的剂量递增。
UNASSIGNED：这项对接受维多珠单抗治疗的IBD患者的真实世界有效性数据的合成表明，在逐步增加维多珠单抗维持剂量后，大约一半能够实现或重新获得临床反应。
